Tech Company Financing Transactions
Epicrispr Biotechnologies Funding Round
On 3/26/2025, Epicrispr Biotechnologies raised $68 million in Series B funding from Ally Bridge Group, Solve FSHD and private investors.
Transaction Overview
Company Name
Announced On
3/26/2025
Transaction Type
Venture Equity
Amount
$68,000,000
Round
Series B
Investors
Ally Bridge Group (Lead Investor) (Andrew Lam)
Solve FSHD (Chip Wilson)
Proceeds Purpose
The proceeds will support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7000 Shoreline Court 100
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Epicrispr Biotechnologies is building the world's leading therapeutic platform based on the exciting new technology of epigenetic editing. We were founded by genetic medicine pioneer Stanley Qi, Ph.D., whose fundamental work in epigenetic editing includes the invention of CRISPRa (activation) and CRISPRi (interference). We are translating the powerful potential of epigenetic editing into transformative therapies that can expand the promise of genetic medicine and improve the lives of people with serious diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amber Salzman
Browse more venture capital transactions:
Prev: 3/26/2025: GravitHy venture capital transaction
Next: 3/26/2025: Island Technology venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs